• Product NameLCZ696
• Brief DescriptionInhibitors
• Purification99.75%
• Biological ActivityLCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
• Target NameRAAS inhibitor
• CAS No. 936623-90-4
• Calculated MW 915.98
• Formulation C24H29N5O3C24H29NO55/2H2O3Na
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:CC(C)[C@@H](C([O-])=O)N(C(CCCC)=O)CC1=CC=C(C2=CC=CC=C2C3=NN=N[N-]3)C=C1.O=C(OCC)[C@H](C)C[C@H](NC(CCC([O-])=O)=O)CC4=CC=C(C5=CC=CC=C5)C=C4.[Na+].[Na+].[Na+].O
  Pathways:Endocrinology/Hormones
  Receptor:RAAS
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 9 mg/mL warmed (9.82 mM); Water: 100 mg/mL warmed (109.17 mM); DMSO: 30 mg/mL warmed (32.75 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Gu J, et al. J Clin Pharmacol. 2010, 50(4), 401-414.2. von Lueder TG, et al. Circ Heart Fail. 2015 Jan;8(1):71-8.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting